Frank Reeves, who has served as chief financial officer of Luminex since April 2001, has left the company. The Austin, Texas-based company will use an interim chief financial officer during the search for a permanent replacement. “There were no financial reporting issues that led to this,” Mark Chandler, Luminex’ chairman and CEO told ProteoMonitor’s sister publication BioArray News. “The board just felt that going forward, they wanted to bring in somebody who had more public company experience in the accounting area.”
Oxford GlycoSciences has appointed Don DeGolyer to the board of directors and the position of president of global therapeutics, the Oxford, UK-based company said last week. Since September 2001 DeGolyer has led the commercialization of OGS’ drug products. Before joining OGS, he spent 16 years at Pfizer and Johnson & Johnson, where he served as vice president of marketing and sales.
OGS separately announced that its CEO Michael Kranda would step at the end of the year for “personal family reasons.” The company has initiated a search for a new CEO.
Affinium Pharmaceuticals, formerly known as Integrative Proteomics, has appointed Damian Lamb to serve on its board of directors. Lamb is a co-founder and managing director of Genesys Capital Partners, a venture capital firm based in Toronto.